Opticon to merge with Immune Response Inc:
This article was originally published in Clinica
Opticon Medical, a privately owned development stage company, is to be acquired by Immune Response Inc of Englewood Colorado, in a deal which will give Opticon an OTC listing. Immune ends up with 20% of the equity of the merged company. Opticon, based in Dublin, Ohio, is developing the OPTICON, a proprietary, silicone, disposable, valved urinary tract catheter which does not require a system of collection tubes or bags. Immune has no connection with the Californian company, Immune Response Corporation.